IRCT201107217085N1已完成3 期
oradrenalin versus the combination of Midodrine and Octreotide in the treatment of patients with Hepatorenal syndrome type 1 and 2 referred to Alzahra Hospital since 2011 to 2012
Vice Chancellery for Reserch and Technology, Isfahan University of Medical Sciences, Isfahan, Iran0 个研究点目标入组 22 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Hepatorenal syndrom patients … Exclusion criteria: Improvement of renal function after volume expansion; history of infection, nephrotoxic drug usage or volume loss in recent week; contraindication to Noradrenalin, Midodrine or Octreotide; recent history of gastrointestinal bleeding; severe hepatic encephalopathy; hepatocellular carcinoma; platelet counts lower than 25000 per microliters; international normalized ratio (INR) more than 5; acute coronary syndrome
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Effectiveness of Combination of Midodrine (drug) With Propranolol (drug) in liver diseaseCTRI/2019/12/022451Institute of Liver and Biliary Sciences140
招募中
不适用
To Study Effect of the Combination of Midodrine and Tolvaptan (drug) Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis (Liver Disease).CTRI/2021/09/036265Institute of Liver and Biliary Sciences
已完成
4 期
Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.Renal Impairment in Hepatorenal SyndromeNCT03455322National Hepatology & Tropical Medicine Research Institute60
暂停
不适用
Efficacy and safety of midodrine in refractory or recurrent ascites in children with cirrhosisCTRI/2021/12/038602ILBS
招募中
不适用
Midodrine in liver failureCTRI/2023/01/048926AIG Hospitals